Psoriasis
Conditions
Interventions
Deucravacitinib treatment group:None
Sponsors
Department of Dermatology, The First Affiliated Hospital of Air Force Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Aged 18 years or above, regardless of sex; 2.Clinically diagnosed with moderate-to-severe plaque psoriasis and assessed by the clinician as suitable for treatment with deucravacitinib; 3.Able and willing to comply with follow-up visits; 4.All participants voluntarily agree to participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients who need to receive phototherapy or other systemic treatments that may affect the evaluation of psoriasis; 2.Patients with known or suspected poor compliance; 3.Patients who are judged by the investigator to be unsuitable for participation in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PASI 75/90/100 response rates at weeks 16 and 52 of deucravacitinib treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in PASI 75 response rates among subgroups with different prior treatment backgrounds;Proportion of subjects achieving a DLQI score of 0/1 at week 52 of deucravacitinib treatment;Proportion of subjects achieving a PGA score of 0/1 after 52 weeks of treatment;Proportion of subjects achieving NPASI 75/90/100 response after 52 weeks of treatment;Change from baseline in BSA during the 52-week treatment period;Safety events during 52 weeks of deucravacitinib treatment; | — |
Countries
China
Contacts
Public ContactChen Yu
The First Affiliated Hospital of Air Force Medical University
Outcome results
None listed